Akers Biosciences
Akers Biosciences is a former NASDAQ-listed biotech (Thorofare, NJ) that pivoted from breath-analysis diagnostics to developing novel vaccine candidates for global health challenges; the company is now effectively dormant, delisted, with its website parked.
- Company typePrivate
- Founded1989
- HeadquartersThorofare, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Akers Biosciences firmographics
Firmographics- Name
- Akers Biosciences
- Website
- https://akersbiosciences.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Akers Biosciences is a former NASDAQ-listed biotech (Thorofare, NJ) that pivoted from breath-analysis diagnostics to developing novel vaccine candidates for global health challenges; the company is now effectively dormant, delisted, with its website parked.
- Ownership category
- akta.pro rank
Akers Biosciences industry classification
Industry- Product category
- Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
Keywords
Where Akers Biosciences is headquartered
LocationHeadquarters
- HQ city
- Thorofare
- HQ country
- United States
- HQ region
- North America
Markets served
Akers Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Akers Biosciences product offering
Product offeringCore offering
Akers Biosciences was a biotechnology company dedicated to solving global health challenges, with a focus on developing novel vaccine candidates. Historically, the company was also associated with the breathalyzer/breath analysis market, developing rapid diagnostic breath tests for health and safety applications. The company's website is currently parked and not operational, indicating the company is no longer actively operating its primary web presence.
Differentiator
Problem solved
Functional benefit
Products and services
- Novel Vaccine Candidates
- Breath Diagnostic Tests
Companies that use Akers Biosciences
Customer profileIdeal customer profiles2 records
Akers Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Akers Biosciences competitors and assessment
Company assessmentBroad incumbents
- Abbott Laboratories: Diversified global healthcare company with a broad diagnostics portfolio including point-of-care breath analysis. Comparable to Akers' legacy diagnostics business as a broad incumbent with overlapping capabilities.
- Drägerwerk: German medical and safety technology company historically competing in the breathalyzer market alongside Akers. Relevant as a peer given Akers' legacy business in breath-analysis devices prior to its vaccine pivot.
Direct peers
- GeoVax Labs: Clinical-stage biotechnology company developing novel vaccines and immunotherapies against infectious diseases and cancer. Comparable in scale and focus to Akers' vaccine candidate pipeline positioning.
- Vaxart: Clinical-stage biotechnology company developing oral recombinant vaccines delivered by tablet. A similarly small, single-focus vaccine developer targeting global health challenges — closely aligned with Akers' described mandate.
- Lifeloc Technologies: Specialty manufacturer of professional breath alcohol testing devices, comparable to Akers' legacy breath-analysis product line. A direct peer in the historical breathalyzer business.
- Novavax: Clinical-stage vaccine developer with a platform approach to novel vaccine candidates, including recombinant protein and nanoparticle vaccines. Directly comparable to Akers' stated focus on novel vaccine development, although operating at vastly larger scale.
- Intoximeters: Manufacturer of breath alcohol testing instruments, historically cited as a competitor in the breath-analysis market Akers once addressed. Relevant as a legacy-business peer from Akers' pre-pivot commercial era.
- Dynavax Technologies: Biopharmaceutical company focused on developing and commercializing novel vaccines, including its CpG 1018 adjuvant used in hepatitis B and COVID-19 vaccines. Comparable to Akers as a small-cap vaccine-focused biotech.
Market position
Customer concentration
Akers Biosciences social profiles
Digital presenceAkers Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Akers Biosciences leadership team
Management profileNumber of profiles
Profiles5 records
Akers Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Akers Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Akers Biosciences
What does Akers Biosciences do?
Akers Biosciences was a biotechnology company dedicated to solving global health challenges, with a focus on developing novel vaccine candidates. Historically, the company was also associated with the breathalyzer/breath analysis market, developing rapid diagnostic breath tests for health and safety applications. The company's website is currently parked and not operational, indicating the company is no longer actively operating its primary web presence.
When was Akers Biosciences founded?
Akers Biosciences was founded in 1989. It employs 11 to 50 people.
Where is Akers Biosciences based?
Akers Biosciences is headquartered in Thorofare, United States, in the North America region.
Who are Akers Biosciences's main competitors?
Broad incumbents on record are Abbott Laboratories and Drägerwerk. Direct peers are GeoVax Labs, Vaxart, Lifeloc Technologies, Novavax, Intoximeters and Dynavax Technologies.
Does Akers Biosciences have an API?
No public API is recorded for Akers Biosciences.
What industry is Akers Biosciences in?
Akers Biosciences's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.